Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Completed · Phase 3 · Has a placebo group

Conditions studied: Encephalitis, Japanese Encephalitis

In brief

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Key facts

Study ID

NCT00314132

Run by

Sanofi

People needed

2004

Starts

2005-10-01

Expected to finish

2006-11-01

Last updated by the study team

2012-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Informed consent obtained from the subject.
• Aged 18 years or above at screening.
• In good general health
• Subject available for the study duration
• For female subjects (of child bearing potential) a negative pregnancy tests at Screening and Day 0.

You may not qualify if…

• A history of vaccination against or infection with JE.
• Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.
• History of thymoma, thymic surgery (removal) or myasthenia gravis.
• Clinically significant abnormalities on laboratory assessment
• Anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).
• Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 30.
• Administration of another vaccine or antiviral within 30 days preceding the Screening visit or up to Day 30.
• Physical examination indicating any clinically significant medical condition.
• Oral temperature >38°C (100.4°F) or acute illness within 3 days prior to inoculation.
• Intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to Day 30.
• Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface Antigen.
• Lactation or intended pregnancy in female subjects.
• Excessive alcohol consumption, drug abuse, significant psychiatric illness.
• A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges).
• Participation in another clinical study within 30 days of the screening visit for this study.
• Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved with the management of the study.
• Any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.

Where it is running

• Study site — Burbank, California, United States
• Study site — Costa Mesa, California, United States
• Study site — Davis, California, United States
• Study site — San Francisco, California, United States
• Study site — Vallejo, California, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Pembroke Pines, Florida, United States
• Study site — Iowa City, Iowa, United States
• Study site — Overland Park, Kansas, United States
• Study site — Bardstown, Kentucky, United States
• Study site — Livonia, Michigan, United States
• Study site — Sprnigfield, Missouri, United States
• Study site — Omaha, Nebraska, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Fort Worth, Texas, United States
• Study site — Darlinghurst, Australia
• Study site — Enoggera, Australia
• Study site — Heidelbeg West, Australia
• Study site — Kippa-Ring, Australia
• Study site — Mill Park, Australia
• Study site — Toorak Gardens, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.